CHARISMA
| Endpoint | Clopidogrel plus ASA (N = 7802) | Placebo plus ASA (N = 7801) | Relative Risk (95% CI) | P- Value |
|---|---|---|---|---|
| Severe bleeding | 130 (1.7) | 104 (1.3) | 1.25 (0.97–1.61) | 0.09 |
| Fatal bleeding | 26 (0.3) | 17 (0.2) | 1.53 (0.83–2.82) | 0.17 |
| Primary intracranial haemorrhage | 26 (0.3) | 27 (0.3) | 0.96 (0.56–1.65) | 0.89 |
| Moderate bleeding | 164 (2.1) | 101 (1.3) | 1.62 (1.27–2.10) | <0.001 |
References
Bhatt et al. N Eng J Med 2006; 354 (16): 1706-1717.
PubMed Abstract
